Abstract 667P
Background
A relationship between inflammatory markers and cancer progression has been suggested. Several studies in different types of tumors have found that NLR and PLR are associated with prognosis. A high NLR was linked to shorter OS in p with metastatic castration-resistant prostate cancer. However, the role of NLR and PLR in mCSPC has not been explored. We have examined the potential prognostic impact of NLR and PLR in p with mCSPC treated with D plus ADT.
Methods
We retrospectively analyzed 100 p with mCSPC treated with D plus ADT from 2015 to 2019 at centers of the Catalan Institute of Oncology (Catalunya, Spain). For the present study, we have classified these p according to extent of disease. Those with ≥five bone metastases and/or visceral metastases were defined as “high-volume” (HV; n=60), and all other p were defined as “low-volume” (LV; n=40). We explored the association of pretreatment NLR and PLR with OS in all p and in the HV and LV subgroups.
Results
Pretreatment NLR and PLR were successfully determined in 95 p. 67 p (70%) had low NLR (<3) and 28 p (30%) had high NLR (≥3), while 53 p (56%) had low PLR (<130) and 42 (44%) had high PLR (≥130). No significant differences in OS were observed according to NLR. p with high PLR showed a non-significant trend towards longer OS than those with low PLR (not reached [NR] vs 36.7 months; P=0.09). The multivariate analysis identified NLR (HR 0.34; 95% CI 0.1-1.2; P=0.09) and PLR (HR 0.32; 95% CI 0.12-0.90; P=0.03) as independent markers of OS. In the subgroup of LV p, there were no differences in OS according to PLR, but in HV p, there was a trend towards longer OS among p with high PLR (P=0.08).
Conclusions
In contrast with previous studies, we have found that both high PLR and high NLR may have an effect on longer OS in mCSPC p treated with D plus ADT. Results were confirmed in the subgroup of HV p but not in that of LV p.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.